Search

Your search keyword '"Gardini, Andrea Casadei"' showing total 4 results
Start Over Author "Gardini, Andrea Casadei" Journal scientific reports
4 results on '"Gardini, Andrea Casadei"'

2. Circulating microRNAs as biomarkers for stratifying different phases of liver cancer progression and response to therapy.

Author

D'Abundo, Lucilla, Bassi, Cristian, Callegari, Elisa, Moshiri, Farzaneh, Guerriero, Paola, Michilli, Angelo, Mora, Fernanda, Gardini, Andrea Casadei, Sangiovanni, Angelo, Piscaglia, Fabio, Sabbioni, Silvia, Gramantieri, Laura, and Negrini, Massimo

Subjects
NUCLEOTIDE sequencing, LIVER cancer, HEPATOCELLULAR carcinoma, BLOOD serum analysis, LIVER diseases
Abstract

Hepatocellular carcinoma (HCC) is the most common liver cancer and is among the leading causes of cancer-related death worldwide. There is no reliable biomarker for the early diagnosis of HCC. Circulating microRNAs (miRNAs) have attracted attention as potential biomarkers of disease. By small-RNA next-generation sequencing, the analysis of serum miRNAs led to the identification of molecular signatures able to discriminate advanced HCC from early HCC (n = 246); advanced HCC from CIRRHOSIS (n = 299); advanced HCC from HEALTHY (n = 320); HEALTHY from early HCC (n = 343); and HEALTHY from CIRRHOSIS (n = 414). Cirrhotic patients and early HCC patients exhibited similar serum miRNA profiles, yet a small number of miRNAs (n = 57) were able to distinguish these two classes of patients. A second objective of the study was to identify serum miRNAs capable of predicting the response to therapy in patients with advanced HCC. All patients were treated with sorafenib as first-line therapy: 24 were nonresponsive and 24 responsive. Analysis of circulating miRNAs revealed a 54 miRNAs signature able to separate the two subgroups. This study suggested that circulating miRNAs could be useful biomarkers for monitoring patients with liver diseases ranging from cirrhosis to advanced HCC and possibly predicting susceptibility to first-line treatment based on sorafenib. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

3. The correlation between LDH serum levels and clinical outcome in advanced biliary tract cancer patients treated with first line chemotherapy

Author

Faloppi, Luca, primary, Del Prete, Michela, additional, Gardini, Andrea Casadei, additional, Santini, Daniele, additional, Silvestris, Nicola, additional, Bianconi, Maristella, additional, Giampieri, Riccardo, additional, Valgiusti, Martina, additional, Brunetti, Oronzo, additional, Bittoni, Alessandro, additional, Andrikou, Kalliopi, additional, Lai, Eleonora, additional, Dessì, Alessandra, additional, Cascinu, Stefano, additional, and Scartozzi, Mario, additional

Published
2016
Full Text
View/download PDF

4. Metronomic capecitabine versus best supportive care as second-line treatment in hepatocellular carcinoma: a retrospective study

Author

Giorgia Marisi, Martina Valgiusti, Emiliano Tamburini, Andrea Casadei Gardini, Britt Rudnas, Francesco Giuseppe Foschi, Oronzo Brunetti, Flavia Foca, Davide Tassinari, Stefano Cascinu, Luca Faloppi, Salvatore Pisconti, Giovanni Luca Frassineti, Giorgio Ercolani, Mario Scartozzi, Nicola Silvestris, Andrea Casadei Gardini, Flavia Foca, Mario Scartozzi, Nicola Silvestri, Emiliano Tamburini, Luca Faloppi, Oronzo Brunetti, Britt Rudna, Salvatore Pisconti, Martina Valgiusti, Giorgia Marisi, Francesco Giuseppe Foschi, Giorgio Ercolani, Davide Tassinari, Stefano Cascinu, Giovanni Luca Frassineti, Gardini, Andrea Casadei, Foca, Flavia, Scartozzi, Mario, Silvestris, Nicola, Tamburini, Emiliano, Faloppi, Luca, Brunetti, Oronzo, Rudnas, Britt, Pisconti, Salvatore, Valgiusti, Martina, Marisi, Giorgia, Foschi, Francesco Giuseppe, Ercolani, Giorgio, Tassinari, Davide, Cascinu, Stefano, and Frassineti, Giovanni Luca

Subjects
Oncology, Adult, Male, medicine.medical_specialty, Antimetabolites, Antineoplastic, Carcinoma, Hepatocellular, Article, Capecitabine, 03 medical and health sciences, 0302 clinical medicine, Internal medicine, Carcinoma, medicine, Combined Modality Therapy, Humans, Progression-free survival, Adverse effect, Aged, Neoplasm Staging, Proportional Hazards Models, Retrospective Studies, Aged, 80 and over, Multidisciplinary, Proportional hazards model, business.industry, Liver Neoplasms, capecitabina, hepatocellular carcinoma, best supportive care, Retrospective cohort study, Middle Aged, medicine.disease, Treatment Outcome, 030220 oncology & carcinogenesis, Hepatocellular carcinoma, Administration, Metronomic, Retreatment, 030211 gastroenterology & hepatology, Female, business, medicine.drug
Abstract

Preliminary studies suggest that capecitabine may be safe and effective in HCC patients. The aim of this study was to retrospectively evaluate the safety and efficacy of metronomic capecitabine as second-line treatment. This multicentric study retrospectively analyzed data of HCC patients unresponsive or intolerant to sorafenib treatment with metronomic capecitabine or best supportive care (BSC).Median progression free survival was 3.1 months in patients treated with capecitabine (95%CI: 2.7–3.5). Median overall survival was 12.0 months (95% CI: 10.7–15.8) in patients receiving capecitabine, while 9.0 months (95% CI: 6.5–13.9) in patients receiving BSC. The result of univariate unweighted Cox regression model shows a 46% reduction in death risk for patients on capecitabine (95%CI: 0.357–0.829; p =0.005) compared to patients receiving BSC alone. After weighting for potential confounders, death risk remained essentially unaltered (45%; 95%CI: 0.354–0.883; p = 0.013). Metronomic capecitabine seems a safe second-line treatment for HCC patients in terms of management of adverse events, showing a potential anti-tumour activity which needs further evaluation in phase III studies.

Published
2017

Catalog

Books, media, physical & digital resources
See catalog results